Abstract Based on its proven anabolic effects on bone in osteoporosis patients, recombinant parathyroid hormone (PTH 1-34 ) has been evaluated as a potential therapy for skeletal repair. In animals, the effect of PTH 1-34 has been investigated in various skeletal repair models such as fractures, allografting, spinal arthrodesis and distraction osteogenesis. These studies have demonstrated that intermittent PTH 1-34 treatment enhances and accelerates the skeletal repair process via a number of mechanisms, which include effects on mesenchymal stem cells, angiogenesis, chondrogenesis, bone formation and resorption. Furthermore, PTH 1-34 has been shown to enhance bone repair in challenged animal models of aging, inflammatory arthritis and glucocorticoid-induced bone loss. This pre-clinical success has led to off-label clinical use and a number of case reports documenting PTH 1-34 treatment of delayedunions and non-unions have been published. Although a recently completed phase 2 clinical trial of PTH 1-34 treatment of patients with radius fracture has failed to achieve its primary outcome, largely because of effective healing in the placebo group, several secondary outcomes are statistically significant, highlighting important issues concerning the appropriate patient population for PTH 1-34 therapy in skeletal repair. Here, we review our current knowledge of the effects of PTH 1-34 therapy for bone healing, enumerate several critical unresolved issues (e.g., appropriate dosing regimen and indications) and discuss the long-term potential of this drug as an adjuvant for endogenous tissue engineering.
Introduction
Parathyroid hormone (PTH) is a major systemic regulator of calcium homeostatsis (Harada and Rodan 2003) . It is released from the parathyroid gland in response to hypocalcemia and increases serum calcium concentration by promoting osteoclast-mediated bone resorption, calcium reabsorption in the kidneys and intestinal absorption of calcium through the production of the active vitamin D metabolite (1,25-dihydroxy vitamin D) . Therefore, continuous exposure to PTH leads to hypercalcemia and a decrease in bone volume, which is referred to as its catabolic effect. However, it has long been known that intermittent (once daily), exogenously administered PTH leads to an anabolic effect on bone and the cellular and molecular mechanisms involved have been reviewed (Jilka 2007) . As a result of this unique mechanism of action on bone, PTH has been approved as the only anabolic therapy for postmenopausal osteoporosis (Neer et al. 2001) . Considering that bone formation is critical for fracture healing, there is also a strong rationale for PTH therapy for skeletal repair.
To date, several forms of PTH, including full-length human PTH (PTH ) and the N-terminal 1-34 amino acid peptide of human PTH (PTH 1-34 ), have been developed for the treatment of metabolic bone diseases. Among them, PTH , which is generically referred to as teriparatide, has been extensively studied based on investigations of PTH fragment analogs that have assigned the major determinants of receptor-binding affinity and intracellular signaling through cAMP to this peptide. Although no head-to-head comparison studies have been carried out between PTH 1-34 and full-length native PTH in terms of their effects on bone, the activity of PTH 1-34 is considered to be equivalent to that of PTH . Another major consideration that has led to the clinical development of PTH 1-34 vs. PTH is that industrial scale production of the recombinant peptide can be most cost-effectively achieved by fermentation in Escherichia coli, followed by standard protein purification. As such, PTH was the first molecule to be approved for osteoporosis therapy and is currently used worldwide. Therefore, most of the studies referred to in this review involve data on PTH 1-34 . Since Andreassen et al. first reported the efficacy of intermittent PTH 1-34 therapy on rat tibial fracture healing in 1999 (Andreassen et al. 1999) , a number of studies have shown that this treatment enhances skeletal repair regardless of the skeletal site and mode of bone healing . These studies suggest that PTH 1-34 enhances not only bone remodeling but also osteogenesis and chondrogenesis during skeletal repair, thereby leading to dramatic effects on bone healing. Although local therapy by using growth factors such as bone morphogenetic protein (BMP)-2 and BMP-7 is another attractive option as an adjuvant therapy for skeletal repair based on the success of their use in spine fusion surgery (Einhorn 2003) , PTH 1-34 therapy has some advantages over local growth factor therapy. Local growth factor therapy requires surgical implantation with a carrier material at the lesion site and is only effective for maximum of a few days. In contrast, PTH 1-34 therapy can be applied to any type of skeletal disorders including the cases that would be treated non-surgically (i.e., cervical spine fractures) and can be commenced at any time. In addition, PTH 1-34 therapy can be continued throughout the healing period.
The aim of the present article is to provide an overview of the published studies that demonstrate the efficacy of PTH 1-34 therapy in a variety of skeletal repair models and to review our current knowledge of the mechanism of PTH 1-34 action on bone healing. In addition, we will discuss the potential clinical application of PTH 1-34 therapy for skeletal repair and highlight the remaining issues that must be resolved to achieve clinical success.
Effects of PTH 1-34 therapy on skeletal repair in animal models
Whereas a variety of skeletal repair models have been investigated to examine the efficacy of systemic intermittent PTH 1-34 therapy, the vast majority of this research has been on long bone fracture healing. However, pre-clinical studies of PTH 1-34 therapy on membranous bone formation, critical sized bone defects, spinal arthrodesis and distraction osteogenesis have also been published. Additionally, the efficacy of PTH 1-34 therapy has been tested in impaired bone healing models such as aging, estrogen deficiency, inflammatory-erosive arthritis and steroid-use, as described below.
Long bone fracture/osteotomy models The efficacy of PTH 1-34 therapy (60 or 200 μg/kg per day) on long bone healing at 20 and 40 days was first reported by Andreassen et al. (1999) in the rat tibial fracture model. The high dose increased the ultimate load and the external callus volume by 75% and 99%, respectively, on day 20 and by 175% and 72%, respectively, on day 40, whereas the low dose had no effects on day 20 but demonstrated 132% and 42% increases, respectively, at 40 days after fracture. These treatments also increased the bone mineral content (BMC) of the callus. One concern with this study and several others that replicated the results, is that the doses of PTH 1-34 were suprapharmacological. To address this, Alkhiary et al. (2005) tested the efficacy of 5 and 30 μg/kg per day in a rat closed femur fracture model. The results showed that high dose PTH 1-34 markedly increased the torsional strength, stiffness, BMC, bone mineral density (BMD) and cartilage volume, whereas the low dose had no significant effects by day 21. However, on day 35, both groups showed significant increases in BMC and BMC and total bone volume. Although biomechanical properties significantly increased in the high dose group, the low dose treatment was similar to the placebo at this time.
Toward a clinical translation of this therapy, Manabe et al. (2007) investigated the effect of PTH 1-34 on fracture healing in a primate femoral osteotomy model. The animals received vehicle, low dose PTH (0.75 μg/kg) or high dose PTH (7.5 μg/kg) twice a week, from 3 weeks before surgery to 26 weeks after surgery. All the animals achieved complete union by 26 weeks after surgery; however, PTH 1-34 -treated animals showed superior biomechanical and matrix properties at the fracture site, indicating that PTH 1-34 accelerated the restoration of structural and mechanical properties in a fractured femur.
Cortical bone defect (membranous bone formation) models Different from long bone fracture, which heals by the combination of endochondral bone formation and membranous bone formation, the primary mode of bone healing in cortical bone defects is membranous ossification. Thus, in order to assess PTH 1-34 effects on membranous bone healing, Komatsu et al. (2009) conducted a longitudinal analysis of bone regeneration in a rat femoral cortical bone defect model. After making 2-mm circular defects in the femoral diaphyses, rats were treated for 5 weeks with PTH 1-34 (0, 3, 10, or 30 μg /kg per day). Longitudinal microCT (computer tomography) analyses demonstrated dose-dependent PTH 1-34 -enhanced cortical bone healing as evidenced by increased BMD. Similar results were also obtained in a rat calvarial defect model (5 mm diameter) by using 60 μg/kg per day PTH 1-34 (Andreassen and Cacciafesta 2004) . Thus, PTH 1-34 is equally effective for endochondral and intramembranous bone healing.
Massive structural allografting for critical sized bone defect model Perhaps the greatest opportunity for PTH 1-34 adjuvant therapy is for critical bone defects (>3 cm), which remain a major challenge for reconstructive surgery. Although massive structural allografts are the gold standard, their limited osteogenesis and lack of remodeling are directly associated with the 23%-43% clinical failure rate (Awad et al. 2007 ). To address this, Reynolds et al. (2011) evaluated delayed 40 μg/kg per day PTH 1-34 from 1 to 5 weeks post-operation in a mouse model of 4-mm-long femoral allografting. The results demonstrated significantly increased graft-host integration, plus callus and trabecular bone formation, as measured by microCT. In similar studies, Jacobson et al. (2010) reported these PTH 1-34 effects after using an inorganic scaffold instead of an allograft.
Spinal arthrodesis models
Spinal arthrodesis (fusion) surgery is the standard treatment for degenerative and traumatic spine diseases that are associated with severe neck or back pain and, sometimes, neurologic problems. The lengthy healing period and the fact that bony fusion is never achieved in many cases remain serious problems. Consequently, PTH 1-34 has the potential to be an efficient adjuvant therapy for spinal fusion, an aspect that has been studied in animal models (Abe et al. 2007; Lawrence et al. 2006; Lehman et al. 2010; O'Loughlin et al. 2009 ). All these studies have reached a similar conclusion that PTH 1-34 therapy improves the fusion success rate and accelerates the time to achieve fusion.
Distraction osteogenesis models
Distraction osteogenesis is used for leg, mandible and maxilla lengthening in the treatment of congenital disorders, trauma and tumors. The main problem with this method is that the time until full recovery can be up to a year, partly because of the time needed for the newly formed bone to consolidate and restore mechanical strength. Consistent with the aforementioned skeletal repair models, PTH 1-34 therapy has been demonstrated to increase mechanical strength and callus mineralization in rat and rabbit limb-lengthening models (Aleksyniene et al. 2009; Seebach et al. 2004 ). Of note is that the significant effects of PTH 1-34 therapy in the rabbit model are limited to the consolidation period suggesting that only short-course treatment is needed.
Impaired bone healing models
Another important potential application for PTH 1-34 therapy is in the setting of impaired bone healing from senescence, glucocorticoid-use, inflammatory-erosive arthritis and the menopause. To assess the effects of PTH 1-34 on aged animals, Andreassen and colleagues gave 27-month-old rats high-dose (200 μg/kg per day) therapy and analyzed tibial fracture healing in old versus young rats (Andreassen et al. 1999 (Andreassen et al. , 2001 ). The results demonstrated that, despite marked differences in the healing patterns between young and aged animals, PTH 1-34 therapy significant enhanced callus formation in both groups. Moreover, the drug effects were more robust on callus bone formation in aged rats, whereas callus volume remained unchanged from day 21 to day 56 in aged rats, indicating that PTH 1-34 had limited effects on callus remodeling in aged rats.
Glucocorticoids (GC) are known to induce osteopenia via apoptosis of osteoblasts and osteocytes and to decrease osteoblast development and bone formation. Therefore, chronic GC administration is considered to impair bone healing. Consistently, GC has also been shown to be detrimental to fracture healing. Bostrom et al. (2000) have tested whether PTH-related peptide (PTHrP) treatment enhances fracture healing in rabbits receiving GC and have found that only 15% of the osteotomies achieve radiographic union at 6 weeks in the GC-treated group, whereas over 80% of the osteotomies achieve union at 6 weeks in the untreated control group. PTHrP improves the union rate and increases the radiographic intensity and mechanical strength of the osteotomy site. Although the mechanism by which PTH and PTHrP improve bone healing in GC-treated animals is not completely understood, studies suggest that they suppress osteoblast apoptosis and osteoblast dysfunction (Jilka et al. 1999; Yao et al. 2008) .
Inflammatory-erosive arthropathies, such as rheumatoid arthritis (RA), cause focal bone loss that leads to joint damage considered to be irreversible. However, the potential to repair these osteolytic lesions with PTH has been demonstrated in a mouse model of RA (Redlich et al. 2004) . As many RA patients are postmenopausal women with osteoporosis, data concerning the effects of PTH 1-34 on focal erosions should be forth-coming from clinical studies of on-label use.
Estrogen deficiency is also considered as a risk factor for impaired fracture healing. Kim and Jahng (1999) have demonstrated that fracture healing in ovariectomized rats is impaired compared with that in sham-operated controls and that PTH 1-34 treatment augments mechanical strength and callus bone formation during fracture healing. Nozaka et al. (2008) suggest that this PTH 1-34 effect is attributable to the proliferation of osteoprogenitor cells in the early phase of healing and that PTH 1-34 increases osteoblastogenesis by decreasing adipogenesis, which is known to occur during estrogen deficiency.
Tissue-engineered bone regeneration models with local administration of PTH Some researchers propose local PTH 1-34 therapy combined with scaffold materials for bone regeneration. Jung et al. (2007) have demonstrated that an arginine-glycine-aspartic acid modified polyethylene glycol-based matrix containing covalently bound peptides of the PTH 1-34 enhances bone regeneration in a canine mandible bone defect simulating an alveolar defect with a circular gap of 1.5 mm. Arrighi et al. (2009) have developed a transglutaminase substrate for binding to fibrin as a delivery and cell-invasion matrix with an intervening plasmin-sensitive link to the PTH 1-34 fragment; they have revealed that this scaffold material with PTH 1-34 enhances the bone regeneration of cylindrical drill defects (8 mm in diameter, 13 mm in depth) in the femur and humerus of female sheep. Although an explanation as to why local therapy (continuous release of PTH 1-34 to the lesion) is as effective as intermittent systemic therapy remains elusive, local therapy seems to have advantages over systemic therapy in that it allows cost to be decreased and painful daily injections to be avoided.
Mechanism of PTH action on bone repair
The studies of various skeletal repair models indicate that PTH 1-34 has multiple mechanisms of action. Cellular mechanisms involved in PTH 1-34 -stimulated bone repair include the proliferation and differentiation of mesenchymal stem cells (MSC), chondroprogenitors and osteoprogenitors, chondrocyte maturation, the production of bone matrix proteins and osteoclastogenesis.
Mesenchymal cell proliferation and differentiation
One of the most prominent effects of PTH 1-34 on bone repair is to enhance the proliferation and differentiation of MSC in the early phase of bone healing, as has been demonstrated in a rat model by Nakajima et al. (2002) . These investigators also report PTH 1-34 -induced proliferation of chondroprogenitors at the fracture site when using the same rat fracture model (Nakazawa et al. 2005) . Their studies indicate that increases in both osteoprogenitors and chondroprogenitors attributable to PTH 1-34 -induced proliferation and differentiation contribute to increased callus formation during fracture healing.
At the molecular level, Kaback et al. (2008) have shown that PTH 1-34 enhances MSC differentiation into osteoblasts via the induction of osterix and Runx2 expression in vitro. They have subsequently demonstrated that 40 μg/kg per day PTH 1-34 increases osterix expression at the fracture site in vivo. This treatment also increases the expression of osteoblastic marker genes including type 1 collagen and osteocalcin. Thus, systemic PTH 1-34 has direct effects on MSC and osteoblast gene expression.
Endochondral bone formation
A hallmark of PTH 1-34 therapy during fracture healing is increased cartilaginous callus formation. This appears to occur through a complicated mechanism that involves chondrogenesis, osteogenesis and delayed chondrocyte hypertrophy and remodeling. Okazaki et al. (2003) have shown that the PTH/PTHrP receptor (PPR) is expressed in MSC, proliferating chondrocytes and early hypertrophic chondrocytes but not in hypertrophic chondrocytes in cartilaginous callus during fracture repair. They have also demonstrated that PPR is expressed in osteoblasts and osteocytes in bony callus. These results indicate that PTH 1-34 targets MSC, chondrocytes and osteoblasts during endochondral bone healing. Kakar et al. (2007) performed a comprehensive investigation of PTH 1-34 actions on endochondral bone formation using a mouse closed femoral fracture model. Mice were treated with 30 μg/kg per day or a placebo for 14 days after fracture and the results showed that PTH 1-34 preferentially enhanced chondrogenesis over osteogenesis (three-fold). This enhanced chondrogenesis leads to increased cartilaginous callus formation in the early phase of fracture repair but thereafter PTH 1-34 enhances chondrocyte maturation and mineralization in the fracture callus, as evidenced by both an earlier peak in Sox5 expression and the corresponding earlier induction of type X collagen. To understand the counterintuitive actions of PTH 1-34 on chondrocyte proliferation and maturation, knowledge about the PTHrP/ Indian hedge-hog (IHH) regulatory system in the growth plate during bone development might be helpful. Kakar et al. (2007) have shown that PTH-treated bones initially increase their PTHrP expression during the earliest timepoints (days 2-3) and concomitantly decrease their IHH expression. Since PTHrP primarily maintains chondrocytes in a proliferative phase, PTH treatment presumably increases their proliferation through PTHrP during this phase. Following this phase, PTHrP expression is found to be transiently decreased in PTH-treated bones; this allows chondrocytes to initiate maturation. Further molecular analyses have revealed that PPR signaling leads to the induction of the wnt/β-catenin pathways. Immunohistochemistry and Western blot analyses have shown that nuclear β-catenin levels in the PTH 1-34 -treated bones are transiently decreased on day 5, corresponding to chondrogenic cell recruitment into the callus. Thereafter, nuclear β-catenin levels increase again to support osteoblast differentiation and activation. These studies highlight the pleiotropic effects of PTH 1-34 on endochondral bone formation and the need for additional research to clarify its exact mechanisms of action.
Membranous bone formation PTH 1-34 also has important effects on membranous ossification as has been demonstrated in bone-defect and bonechamber models Komatsu et al. 2009; Skripitz et al. 2000) . These studies have provided histological evidence that PTH dose-dependently induces osteogenesis within defects, especially at endocortical surfaces and in intramedullary space. In the bone-chamber studies, PTH has been shown to increase the trabecular bone density but not to affect the bone-ingrowth distance, indicating that the drug effects are more robust at the endosteal surface and on newly formed trabecular bone versus periosteal surfaces. Systemic and local bone formation markers including serum procollagen type I N-terminal propeptide and mRNA expression of collagen1a2 and osteocalcin have all been revealed to increase on PTH treatment of the bone-defect model, suggesting that PTH treatment increases osteoblastic activity and the proliferation and differentiation of osteoprogenitor cells during membranous bone formation. Modulation of insulin-like growth factor I (IGF-I) might also be an important mechanism by which PTH 1-34 enhances osteoblastic activity. Nakajima et al. (2002) have demonstrated that the increased expression of bone matrix proteins by PTH 1-34 therapy is accompanied by the enhanced expression of IGF-I during the early stage of rat fracture healing. In addition, other studies have indicated that the anabolic actions of PTH 1-34 on bone formation are mediated by IGF-I. Neutralizing the antibody against IGF-I prevents PTH-induced collagen synthesis but not its mitogenic effect in vitro (Canalis et al. 1989 ). Moreover, IGF-I knockout mice fail to show increased bone formation in response to PTH (Bikle et al. 2002; Miyakoshi et al. 2001 ).
Callus remodeling
After the fractured bone is initially stabilized by cartilage and woven bone, the fracture callus is gradually remodeled to lamellar bone and forms a new cortical shell. Through this osteoclastic and osteoblastic remodeling, the fracture site restores it geometrical and biomechanical environment. Since long-term observation (at least 12 weeks in rodent models) is required to investigate the effects of PTH 1-34 on the entire process of fracture healing including callus remodeling, only a few studies have addressed this question. Komatsubara et al. (2005) have investigated the effects of PTH 1-34 therapy on the late phase of fracture healing, focusing on callus remodeling and geometrical changes in a rat femoral osteotomy model. In their study, 10 or 30 μg/kg PTH 1-34 was administered to rats three times a week and healing was observed at 3, 6 and 12 weeks after surgery. Histomorphometric analysis showed that PTH 1-34 accelerated remodeling of woven bone to lamellar bone in the callus, as evidenced by the increased lamellar bone/ callus area in the PTH 1-34 -treatment groups at 3 weeks after surgery. Additionally, the percent new cortical shell area was demonstrated to be significantly higher in the PTH 1-34 -treatment groups compared with the controls, indicating that PTH 1-34 enhanced cortical shell formation of the fracture callus. Furthermore, the authors confirmed these findings by a study of the monkey femur fracture model (Manabe et al. 2007 ). Interestingly, the total area and the percent bone area of fracture callus were significantly lower in both the low-dose (0.75 μg/kg) and the high-dose (7.5 μg/kg) PTH 1-34 treatment groups than in the control group at 26 weeks after surgery, whereas callus porosity decreased dose-dependently following PTH 1-34 treatment and the mean degree of callus mineralization was significantly higher in the high-dose group versus the placebo control. The ultimate stress and elastic modulus in the fractured femur were also significantly higher in the highdose PTH 1-34 group versus the control. These results suggest that PTH 1-34 accelerates the remodeling process of the fracture callus by shrinking the callus size and increasing the degree of mineralization of the fracture callus, thereby restoring intrinsic material properties.
The cellular mechanisms of PTH 1-34 -stimulated callus remodeling and maturation are largely explained by its effects on osteoblast and osteoclast function. PTH 1-34 is known to increase the bone formation rate via the direct stimulation of osteoblast function and the inhibition of apoptosis that thereby extends the life of osteoblasts (Jilka et al. 1999) . Given that the robust fracture induction of osteoblasts is coupled to their subsequent apoptosis during bone repair (Li et al. 2002) , the effect of PTH 1-34 on osteoblasts is amplified during this process. Moreover, PTH 1-34 sustains osteoblast activity during the remodeling period, which thus enhances callus remodeling. Whereas osteoclasts are also considered to play an important role in callus remodeling, opinions on the way that they are affected by PTH 1-34 are divided. Komatsubara and colleagues have reported that PTH 1-34 increases osteoclast density at the fracture callus at 3, 6 and 12 weeks after fracture in the rat (Komatsubara et al. 2005; Nakajima et al. 2002) , whereas others have shown that osteoclast activity does not change with PTH 1-34 treatment, as evidenced by the number of osteoclasts at the fracture callus in the rat (Alkhiary et al. 2005) and by serum tartrate-resistant acid phosphatase (TRAP) activity in the rat fracture model (Nakajima et al. 2002) . Only one study has suggested that PTH 1-34 down-regulates osteoclast activity, as measured by serum TRAP5b levels (Komatsu et al. 2009 ). Meanwhile, studies of osteoporosis treatment suggest that anabolic actions of PTH involve increased osteoclast activity. McClung et al. (2005) have reported that PTH 1-34 therapy significantly increases both bone formation and resorption markers (serum procollagen type I N-terminal propeptide and urinary N-telopeptide corrected for creatinine) in postmenopausal women suffering from osteoporosis. Chavassieux et al. (2008) have shown that PTH 1-34 therapy is ineffective in a patient with pycnodysostosis, which is cathepsin K deficiency. These controversial results suggest that PTH 1-34 induces a transient effect on osteoclast behavior during skeletal repair and the subject thus warrants further investigation.
Clinical perspectives of PTH therapy for skeletal repair
Two potential benefits of PTH 1-34 therapy are relevant to bone repair. The first is accelerated healing, which would allow patients to return more rapidly to normal daily-life and work. Additionally, this therapy might reduce the financial costs and chronic morbidity associated with longterm disability. To test this, a randomized double-blind placebo-controlled study (phase 2 clinical trial) of PTH 1-34 was performed with 102 postmenopausal women who had sustained a distal radius fracture (Aspenberg et al. 2009; Aspenberg and Johansson 2010) . Unfortunately, this study failed to meet its primary prospective endpoint, namely that 40 μg/day teriparatide (double the dose for osteoporosis treatment) would shorten the time to cortical bridging. Although this study did indeed show that 20 μg/day PTH 1-34 accelerated the time to radiographic healing from 9.1 to 7.4 weeks versus the placebo (P=0.006), its results raised the question of clinical significance and of the relevance of any benefits of such a treatment when used for fractures in which a normal healing process could be expected.
The second potential benefit of PTH 1-34 therapy is the enhanced healing in those patients who suffer from delayed or non-unions. Since available adjuvant therapies for impaired bone healing are limited, PTH 1-34 therapy might be a reliable and safe treatment option for these conditions. Clinical case reports of off-label use of PTH 1-34 to aid the healing of delayed-unions support the idea that the drug might be effective as an adjuvant for impaired bone healing. Reynolds et al. (2009) have reported a case in which teriparatide effectively improved bony union between fractured tibial segments that showed no sign of healing 4.5 months after injury. Another case documented the use of teriparatide in a patient with a delayed union of a humeral shaft fracture in which healing was achieved with no other intervention to which the successful outcome could be attributed (Oteo-Alvaro and Moreno 2010). Three case reports of painful delayed unions of odontoid fractures describe successfully outcomes attributable to teriparatide therapy (Rubery and Bukata 2010) . Although these data are only considered to represent anecdotal level IV (case series) evidence, the cases nevertheless involved elderly patients (over 80 years old) with concomitant medical problems such as postmenopausal osteoporosis, vitamin D deficiency and diabetes, whereas the patients in the first two case reports were healthy adult men who had no specific risk factors for impaired union other than high-energy trauma.
Unresolved issues and future directions
Several critical questions must be addressed with regard to the clinical application of PTH 1-34 . The first is whether the osteoporosis treatment dose (20 μg/day) is sufficient for enhancing skeletal repair. Fracture-healing studies in animal models have involved the use of doses that represent supraphysiologic doses of teriparatide in humans; whether these same effects would be seen at lower doses in humans is unclear. Rodent models employ doses of 5-200 (typically 40) μg/kg body weight per day for anabolic effects on skeletal repair, whereas the clinical dose for osteoporosis treatment is 20 μg per day total (which, in a 50-to 80-kg person translates to 0.25-0.4 μg/kg per day). This discrepancy in effective dose is considered to be derived from species differences in terms of the response to and the metabolism of PTH 1-34 . However, a higher dose of PTH than that for osteoporosis might be necessary to enhance skeletal repair in humans. Hence, the effective dose of PTH 1-34 for skeletal repair should be validated by clinical trials because of difficulties in translating the animal dose to human.
Appropriate dosing regimens and indications for PTH 1-34 therapy are also critical issues to be addressed. Although several months of PTH 1-34 treatment for skeletal repair might seem ideal, the potential risk of osteosarcoma needs to be considered, together with the high cost of the drug and the inconvenience of daily subcutaneous injections. Thus, elucidation of the critical period in which PTH 1-34 therapy mediates its significant effect on healing is critical. In the case of trauma, the commencement of PTH 1-34 treatment immediately after injury might be difficult and whether delayed PTH treatment is as effective as immediate treatment is unknown. Furthermore, no clinical information is available with regard to how late PTH 1-34 therapy can be initiated to achieve effective results on delayed union or non-union. PTH 1-34 might be effective for delayed-union as long as bone formation is still active at the fracture site but not for non-union, in which bone formation is no longer active. In a study of distraction osteogenesis, PTH 1-34 therapy during the consolidation period has been shown to be sufficient to give maximum effects on healing (Aleksyniene et al. 2009 ); an ideal treatment window might therefore exist that exerts maximum benefit according to the type of skeletal repair required. Thus, prospective clinical studies are needed to determine the value of PTH 1-34 therapy, which holds great promise for skeletal repair.
